華誼騰訊(00419.HK)旗下「醫智諾」獲國資基金投資 擬5年內IPO
華誼騰訊娛樂(00419.HK)連同附屬公司「醫智諾」公布,與張家港翼唐股權投資合夥企業(有限合夥)訂立「醫智諾」增資協議。增資協議指出,基於「醫智諾」增資完成前之估值為6億元人民幣(下同),新投資者已有條件同意向「醫智諾」作出現金出資合共4,000萬元以獲取「醫智諾」6.25%之股權。
集團指,新投資者主要是以私募基金形式從事股權投資、投資管理、資產管理、科技推廣和應用服務等活動,其最終控制人為張家港高新區投資控股有限公司,是江蘇省張家港市的一間國有獨資公司。是次獲國資企業注資,讓「醫智諾」更能受惠於新投資者所擁有的額外政府、業務及網絡資源,令公司能繼續在中國數字化醫療營銷市場佔龍頭席位。
公司表示,與新投資者訂立「醫智諾」股東協議後,「醫智諾」將竭盡全力在五年內在認可證券交易所首次公開發售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.